MiR-489 modulates cisplatin resistance in human ovarian cancer cells by targeting Akt3

Wu Huijuan(Tianjin Medical University Cancer Institute and Hospital), Quan Hao(Gynecologic Oncology Group), Zhenghua Xiao(Xiaomi (China)), Hua Zhang(Anhui Medical University), Wenxin Liu(Jiujiang University), Ke Wang(Tianjin Medical University Cancer Institute and Hospital)
Anti-Cancer Drugs
April 7, 2014
Cited by 53


Related Papers